Perfused, vascularized 3D human tumour tissue models for predictive preclinical testing

VoxCell is a Canadian biotechnology company developing in vitro preclinical 3D vascularized human tumour tissue models designed to generate more predictive, human-relevant efficacy and safety data for oncology drug development. Our tissues incorporate engineered, reproducible, perfusable vasculature, enabling controlled assessment of delivery, penetration, immune infiltration, endothelial response, and vascular toxicity in ways that conventional 2D and standard 3D systems cannot.

Our models are designed for therapeutic modalities where delivery biology is critical to interpretation, including biologics, ADCs, bispecifics, T cell engagers, and other advanced or immune-mediated modalities. By combining controlled vascular architecture with tumour microenvironment context, VoxCell helps partners generate decision-grade datasets that support earlier and more informed go or no-go decisions.

VoxCell works with biopharma companies, CROs, and research partners through focused pilot studies, therapeutic evaluation programs, and strategic collaborations. In addition to our core tissue model offerings, we also pursue custom model development where there is a strong use case, clear market demand, and downstream commercialization potential.